My primary research interests are:
- The delivery and methods of peritoneal dialysis as well as patient choice in renal replacement therapy.
- Nephrogenic Systemic Fibrosis and Gadolinium Containing Contrast Agents. focusing on epidemiology, mechanism of disease, policy and risk reduction.
- Optimizing the care of patients with chronic kidney disease with particular focus on anemia management and treatment of CKD-Mineral Bone Disorders.
Extensive Research Description
I am primarily interested in improving the delivery and methods of peritoneal dialysis, especially Automated Peritoneal Dialysis and new dialysate solutions. I am also interested in optimizing the care of patients with chronic kidney disease (CKD) with particular focus on anemia management and CKD-MBD, and on the transition to the renal replacement therapy phase.
A recent and active interest has been Nephrogenic Systemic Fibrosis and its association with Gadolinium-based Contrast Agents, focusing on risk reduction and policy. An annual mutli-disciplinary international conference has been held at Yale for the past 3 years, devoted to the issue with the fourth meeting being held in May 2010 in collaboration with the New York Academy of Sciences.
Cancer-related kidney diseases and complications are also within my areas of interest.
- Nephrogenic Systemic Fibrosis: Epidemiology, risk factors and risk estimation
- Nephrogenic Systemic Fibrosis: Therapy
- Nephrogenic Systemic Fibrosis and Imaging: Risk reduction and management
- Nephrogenic Systemic Fibrosis and Imaging: Screening for at-risk patients in MRI
- Anemia management in CKD and hospitalized patients
- Peritoenal Dialysis Physiologic studies
- Kuo PH, Abu-Alfa A, Bucala R, Griffith J, Carlson K, Girardi M, Weinreb J and Cowper S: MRI in the era of nephrogenic systemic fibrosis: Review, controversies and suggestions for risk reduction. Applied Radiology, 2009, ePUB April 09.
- Huen S, Hall I, Topol J, Mahnensmith R, Brewster U and Abu-Alfa A: Successful Use of IP Daptomycin in the Treatment of VRE Peritonitis. Am J Kidney Dis. 2009; 54:538-541.
- Abu-Alfa, AK , Sloan L, Charytan C, Sekkarie M, Scarlata D, Globe D and Audhya P. Darbepoetin alfa The association of darbepoetin alfa with hemoglobin and health-related quality of life in patients with chronic kidney disease not receiving dialysis. Curr
- Abu-Alfa , AK : The Impact of NSF on the Care of Patients with Kidney Disease. Proceedings of the First Annual Symposium on Nephrogenic Systemic Fibrosis and Gadolinium Based MR Contrast Agents. J Am Coll Radiol 2008 5: 45-52.
- Saab G and Abu-Alfa, AK: Nephrogenic systemic fibrosis-Implications for nephrologists. Eur J Radiol. 2008 May 66(2):208-12.
- Kuo, PH, Kanal, M, Abu-Alfa, AK and Cowper, SE: Gadolinium-based MR Contrast Agents and Nephrogenic Systemic Fibrosis. Radiology 2007, 242(3):647-9.
- Saab G and Abu-Alfa, AK: Are Patients with Moderate Renal Failure at Risk for Developing Nephrogenic Systemic Fibrosis? Radiology 2007 244: 930.
- Saab G and Abu-Alfa, AK: Will Dialysis Prevent the Development of Nephrogenic Systemic Fibrosis After Gadolinium-Based Contrast Administration? AJR Am J Roentgenol. 2007 Sep 189 (3): W169.
- Finkelstein F, Healy H, Abu-Alfa, AK, Ahmad A, Brown F, Gehr T, Nash K, Sorkin M and Mujais S, on behalf of the Icodextrin High Transporter Trial Group. Superiority of Icodextrin Compared to 4.25% Dextrose for Peritoneal Ultrafiltration. J Am Soc Nephrol